Asset profile
XmAb5871
Biologic (subtype unspecified)
Evidence outlook · lead readout
NCT02725515 · Systemic Lupus Erythematosus
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT02725515: The study randomized 105 participants to XmAb5871 or placebo and used quadruple blinding. Its clinical primary endpoint was not met: 21 of 50 XmAb5871-treated patients versus 12 of 42 placebo-treated patients avoided loss of disease activity improvement at Day 225 (p=0.1830), despite a favorable statistically significant secondary time-to-loss result.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
54 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 54 same-indication; 21 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| XmAb5871: this drug | Phase 2 | Biologic (subtype unspecified) | CD19 / FcγRIIb | ||
| Anifrolumab | Approved | Monoclonal antibody | Type I interferon receptor, Type I interferon receptor subunit 1 (IFNAR1) | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Belimumab (GSK1550188) | Approved | Monoclonal antibody | BAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS) | ||
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | ||
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | ||
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | ||
| Voclosporin (Lupkynis) | Approved | Small molecule | Calcineurin, Cyclophilin A (leading to calcineurin inhibition) | ||
| APG-2575(Lisaftoclax ) | Phase 3 | Small molecule | BCL-2 | ||
| AZD0120 | Phase 3 | Cell therapy | BCMA / CD19 | ||
| Blinatumomab | Phase 3 | Multispecific antibody | CD19 x CD3 | ||
| Descartes-08 | Phase 3 | Cell therapy | — | ||
| Divozilimab | Phase 3 | Monoclonal antibody | CD20 | ||
| Envudeucitinib | Phase 3 | Small molecule | TYK2 | ||
| Frexalimab | Phase 3 | Monoclonal antibody | CD40 ligand (CD40L / CD154) | ||
| Inebilizumab | Phase 3 | Monoclonal antibody | CD19 |
…and 39 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.